(Q28246258)

1

0 references

Carlota Costa

2

0 references

Yitao Ding

3

0 references

Zhengyun Zou

4

0 references

Lixia Yu

5

0 references

Jose Javier Sanchez

6

0 references

Xiaoping Qian

7

0 references

Hong Chen

8

0 references

Ana Gimenez-Capitan

9

0 references

Fanqing Meng

10

0 references

Teresa Moran

11

0 references

Susana Benlloch

12

0 references

Miquel Taron

13

0 references

Baorui Liu

Journal of the National Cancer Institute

15

0 references

language of work or name

English

0 references

publication date

19 October 2011

0 references

published in

0 references

volume

103

0 references

issue

20

0 references

page(s)

1552-6

0 references

cites work

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Is there a role for second-line chemotherapy in advanced gastric cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Docetaxel: its role in current and future treatments for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

The DNA damage response: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

SUMO in the mammalian response to DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

More modifiers move on DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR326